Los Angeles, CA, United States of America

Charles E McKenna

This inventor holds 27 USPTO granted patents and 8 published patent applications and 2 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: University of Southern California, Biovinc LLC, University of California. Active years: 1984-2026.

USPTO Granted Patents = 27 (Patent Applications = 8)

% Patents Active = 81.5

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 2.8

ph-index = 3

Forward Citations = 67(Granted Patents)

Location History:

Los Angelese, CA (US) (2009)
Los Angeles, CA (US) (1984 - 2021)
Pacific Palisades, CA (US) (1991 - 2022)
Pasadena, CA (US) (2020 - 2023)

Company Filing History:

23 out of 1,693

University of Southern California

University of California

patents

4. 2 out of 3,691

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Centre National De La Recherche Scientifique

patents

7. 1 out of 276

Massachusetts Eye and Ear Infirmary

patents

8. 1 out of 1,853

National Institute of Health and Medical Research

patents

9. 1 out of 1

The United States of America as Represented by the Nih Division of Extramural Inventions and Technology Resources (Deitr)

patent

10. 1 out of 178

Université Grenoble Alpes

patents

11. 2 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1984-2026

Loading Chart...

Areas of Expertise:

Drug Conjugates

Antiviral Compounds

Bisphosphonates

Osteoclast Activity

Small Molecule Enantiomers

Antimicrobial Agents

Fluorogenic Substrates

Heavy Metal Removal

Bromodomain Inhibition

Prodrugs

Pyrophosphate Analogs

Thiophosphonates

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12624058 - Promoiety strategy to enhance drug activity (2026-05-12),

2. 12552806 - Androgen receptor regulation by small molecule enantiomers (2026-02-17),

3. 12285489 - Bone targeted antimicrobial oxazolidinone related compounds, formulations thereof, and uses thereof (2025-04-29),

4. 11840549 - Bisphosphonate quinolone conjugates and uses thereof (2023-12-12),

5. 11400104 - Skeletal removal of bisphosphonates (2022-08-02),

6. 11331391 - Phosphonate-drug conjugates (2022-05-17),

7. 11219697 - Osteoadsorptive fluorogenic substrate of cathepsin k for imaging osteoclast activity and migration (2022-01-11),

8. 10919922 - Broad spectrum antiviral compounds (2021-02-16),

9. 10918647 - Selective bromodomain inhibition of fungal Bdf1 (2021-02-16),

10. 10865220 - Bisphosphonate quinolone conjugates and uses thereof (2020-12-15),

11. 10857165 - Skeletal removal of bisphosphonates (2020-12-08),

12. 9550803 - Method to improve antiviral activity of nucleotide analogue drugs (2017-01-24),

13. 8940313 - Tyrosine-based prodrugs of antiviral agents (2015-01-27),

14. 8431714 - Synthesis of drug conjugates via reaction with epoxide-containing linkers (2013-04-30),

15. 8063209 - Phosphonyl ester conjugates as prodrugs (2011-11-22),

Title: Innovations and Contributions of Charles E McKenna

Introduction

Charles E McKenna, based in Los Angeles, CA, is a prominent inventor with an impressive portfolio of 24 patents. His work focuses on pharmaceutical formulations and methods that have significant implications in the field of biochemistry.

Latest Patents

Among his latest patents is the invention of bisphosphonate quinolone conjugates and their uses. This patent describes bisphosphonate quinolone compounds and formulations that involve a bisphosphonate and a quinolone, allowing for the quinolone to be releasably coupled to the bisphosphonate. Additionally, McKenna has developed methods for making and using these compounds, highlighting their potential therapeutic applications. Another noteworthy patent is focused on the skeletal removal of bisphosphonates. This patent discloses methods and compositions aimed at removing or displacing bisphosphonates within skeletal tissue, further showcasing his innovative approach to pharmaceutical challenges.

Career Highlights

Throughout his career, McKenna has made substantial contributions to the field of pharmaceutical chemistry. He has worked with leading research institutions and companies, including the University of Southern California and Biovinc LLC, where he has been instrumental in advancing drug development and therapeutic strategies.

Collaborations

Charles E McKenna has collaborated with several esteemed professionals, including Boris A Kashemirov and Shuting Sun. These collaborations have enriched his research, resulting in impactful innovations that continue to influence the scientific community.

Conclusion

In summary, Charles E McKenna's contributions to innovation and invention in the field of pharmaceuticals stand as a testament to his expertise and dedication. His patents and collaborative efforts are paving the way for future advancements in medical treatments, reflecting his significant role in the realm of biochemistry.